Awaad Amani S, Alafeefy Ahmed M, Alasmary Fatmah A S, El-Meligy Reham M, Alqasoumi Saleh I
Pharmacognosy Department, College of Pharmacy, Sattam Bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.
Department of Chemistry, Kulliyyah of Science, International Islamic University, Malaysia.
Saudi Pharm J. 2017 Dec;25(8):1125-1129. doi: 10.1016/j.jsps.2017.07.003. Epub 2017 Jul 11.
The Novel target compounds (CP-1-7) were synthesized and tested at doses up to 1000 mg/kg for their entitled activities. They exerted promising results without any behavioral changes and mortality in mice. Therefore, according to the results obtained in our study, it could be categorized as highly safe agents for treating UC since substances possessing LD higher than 50 mg/kg are considered nontoxic. They also possessed a potent anti-ulcerogenic activity with different potentials. The most effective compound was CP-4, it produced 97.7% ulcer protection of control followed by CP-3, which produced 90.3% protection, while the standard drug ranitidine (100 mg/kg) produced 49.2% protection. Compound CP-1 showed lowest activity among the current series, it produced 55.5% protection. The target compounds were significantly more effective than the standard in reducing ulcer index. The anti-ulcerative colitis activity was tested using acetic acid induced colitis model. The curative effect of the tested compounds at a dose of 50 mg/kg oral administration on rats showed a potent anti-ulcerative colitis activity with different potentials. They induced a significant decrease in ulcer score, ulcer area, ulcer index and weight/length of the colon specimens. The percent protection of control colitis ranged from 66.8% for CP-7 to 22.3% for CP-5; however the percent protection for dexamesathone (0.1 mg/kg) was 59.3%. The effect of the tested compounds CP-7 and CP-3 at dose 50 mg/kg were significantly more effective than dexamesathone (0.1 mg/kg) in reducing all parameters. Liver functions were not affected as there is no effect on the activity of both AST and ALT in animals that received the compounds, so the compounds didn't reveal hepatotoxic manifestation. Although, the results on kidney functions showed that, CP-1 slightly elevated blood urea concentration and CP-3 & CP-4 slightly elevated serum creatinine; no apparent nephrotoxic manifestations were recorded.
合成了新型目标化合物(CP-1-7),并以高达1000 mg/kg的剂量对其相应活性进行了测试。它们在小鼠中产生了有前景的结果,且没有任何行为变化和死亡情况。因此,根据我们研究中获得的结果,由于LD高于50 mg/kg的物质被认为无毒,所以它可被归类为治疗溃疡性结肠炎的高度安全药物。它们还具有不同程度的强效抗溃疡活性。最有效的化合物是CP-4,它对对照组产生了97.7%的溃疡保护作用,其次是CP-3,产生了90.3%的保护作用,而标准药物雷尼替丁(100 mg/kg)产生了49.2%的保护作用。化合物CP-1在当前系列中显示出最低的活性,它产生了55.5%的保护作用。目标化合物在降低溃疡指数方面比标准药物显著更有效。使用乙酸诱导的结肠炎模型测试了抗溃疡性结肠炎活性。受试化合物以50 mg/kg口服给药剂量对大鼠的治疗效果显示出不同程度的强效抗溃疡性结肠炎活性。它们使溃疡评分、溃疡面积、溃疡指数以及结肠标本的重量/长度显著降低。对照结肠炎的保护百分比范围从CP-7的66.8%到CP-5的22.3%;然而,地塞米松(0.1 mg/kg)的保护百分比为59.3%。受试化合物CP-7和CP-3在50 mg/kg剂量下在降低所有参数方面比地塞米松(0.1 mg/kg)显著更有效。肝功能未受影响,因为接受化合物的动物中AST和ALT的活性均未受到影响,所以这些化合物未显示出肝毒性表现。尽管如此,肾功能结果显示,CP-1略微提高了血尿素浓度,CP-3和CP-4略微提高了血清肌酐;未记录到明显的肾毒性表现。